Search Results - "Atarashi, Yusuke"

A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies by Noda, Kenta, Matsuda, Kouki, Yagishita, Shigehiro, Maeda, Kenji, Akiyama, Yutaro, Terada-Hirashima, Junko, Matsushita, Hiromichi, Iwata, Satoshi, Yamashita, Kazuto, Atarashi, Yusuke, Watanabe, Shunsuke, Ide, Nobuyuki, Yoshida, Tomokazu, Ohmagari, Norio, Mitsuya, Hiroaki, Hamada, Akinobu

“…The quantitative range and reproducibility of current serological tests for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are not optimized…”
Get full text

Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer by Sakaeda, Kanako, Kurose, Koji, Matsumura, Yuki, Muto, Satoshi, Fukuda, Minoru, Sugasaki, Nanae, Fukuda, Masaaki, Takemoto, Shinnosuke, Taniguchi, Hirokazu, Masuda, Takeshi, Shimizu, Katsuhiko, Kataoka, Yuki, Irino, Yasuhiro, Sakai, Yumiko, Atarashi, Yusuke, Yanagida, Masatoshi, Hattori, Noboru, Mukae, Hiroshi, Nakata, Masao, Kanda, Eiichiro, Oga, Toru, Suzuki, Hiroyuki, Oka, Mikio

“…[Display omitted] •NY-ESO-1 and XAGE1 cancer/testis antigens are highly immunogenic in NSCLC patients.•NY-ESO-1/XAGE1 Abs are potentially antitumor B-cell and…”
Get full text

Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers by Kurose, Koji, Sakaeda, Kanako, Fukuda, Minoru, Sakai, Yumiko, Yamaguchi, Hiroyuki, Takemoto, Shinnosuke, Shimizu, Katsuhiko, Masuda, Takeshi, Nakatomi, Katsumi, Kawase, Shigeo, Tanaka, Ryo, Suetsugu, Takayuki, Mizuno, Keiko, Hasegawa, Takehiro, Atarashi, Yusuke, Irino, Yasuhiro, Sato, Toshiyuki, Inoue, Hiromasa, Hattori, Noboru, Kanda, Eiichiro, Nakata, Masao, Mukae, Hiroshi, Oga, Toru, Oka, Mikio

“…Immune checkpoint inhibitors (ICI) are key drugs in systemic therapy for advanced non-small-cell lung cancer (NSCLC) and have recently been incorporated into…”
Get full text

Abstract 3180: Development of a fully automated immunoassay system for detection of serum NY-ESO-1 and XAGE1 antibodies as biomarkers predicting the clinical efficacy of anti-PD-1 therapy by Sakai, Yumiko, Abo, Hirotaka, Sakaeda, Kanako, Atarashi, Yusuke, Ide, Nobuyuki, Yamaoka, Takaaki, Kurose, Koji, Noda, Kenta, Sato, Toshiyuki, Oga, Toru, Oka, Mikio

“…Abstract Background: Programmed cell death-1 (PD-1) and PD-ligand1 (PD-L1) inhibitors have become standard therapies for advanced non-small-cell lung cancer…”
Get full text

Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1 by Yajima, Hisano, Anraku, Yuki, Kaku, Yu, Kimura, Kanako Terakado, Plianchaisuk, Arnon, Okumura, Kaho, Nakada-Nakura, Yoshiko, Atarashi, Yusuke, Hemmi, Takuya, Kuroda, Daisuke, Takahashi, Yoshimasa, Kita, Shunsuke, Sasaki, Jiei, Sumita, Hiromi, Ito, Jumpei, Maenaka, Katsumi, Sato, Kei, Hashiguchi, Takao

“…Since 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, binds to…”
Get full text

A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer by Sakai, Yumiko, Kurose, Koji, Sakaeda, Kanako, Abo, Hirotaka, Atarashi, Yusuke, Ide, Nobuyuki, Sato, Toshiyuki, Kanda, Eiichiro, Fukuda, Minoru, Oga, Toru, Noda, Kenta, Oka, Mikio

“…•NY-ESO-1 and XAGE1 are major cancer antigens in non-small-cell lung cancer (NSCLC).•Serum NY-ESO-1 and XAGE1 antibody predict clinical benefits with anti-PD-1…”
Get full text